Research programme: MCHR1 protein antagonists - AMRI

Drug Profile

Research programme: MCHR1 protein antagonists - AMRI

Alternative Names: AMR-MCH-1; AMR-MCH-14; AMR-MCH-18; AMR-MCH-2

Latest Information Update: 28 Apr 2016

Price : $50

At a glance

  • Originator AMRI
  • Class Dihydropyridines; Indazoles; Small molecules
  • Mechanism of Action MCHR1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Obesity

Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 28 Apr 2016 The MCHR1 protein antagonists programme is available for licensing as of 28 Apr 2016. http://www.amriglobal.com/
  • 08 Nov 2011 Discontinued - Preclinical for Obesity in USA (PO)
  • 20 Aug 2009 Pharmacodynamics data from a preclinical trial in Obesity presented at the 238th American Chemical Society National Meeting (ACS-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top